Business Wire

BYD Rolled Off Its 7 Millionth New Energy Vehicle

25.3.2024 14:03:00 EET | Business Wire | Press release

Share

On March 25th, BYD, the world's leading manufacturer of new energy vehicles and power batteries, became the world's first automaker to roll off its 7 millionth new energy vehicle, the DENZA N7, which was unveiled at its Jinan factory in China, symbolizing another groundbreaking accomplishment for the brand.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325602328/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BYD rolled off its 7 millionth NEV (Photo: Business Wire)

BYD reached the production of 1 millionth NEV in May 2021 and rapidly multiplied this figure threefold within 18 months, then surpassed 5 million units in merely 9 additional months. In just 7 months from this mark, BYD accelerated to the 7 million milestone, showcasing a robust end-to-end supply chain and the effect of scale. In 2023, BYD's cumulative annual sales of NEV soared to 3.02 million units, solidifying its status as the global leader in NEV sales. A variety of models from its extensive brand portfolio consistently led sales rankings within their individual categories.

Proactively engaging with the international market, BYD quickly expanded its global footprint in 2023, witnessing a surge in overseas new energy passenger car sales that exceeded 240,000 units—a 337% year-on-year growth—making it the top Chinese exporter of NEVs in 2023. Up to now, BYD's new energy passenger vehicles have been introduced to 64 countries and regions globally, with strategic investments in manufacturing facilities in Thailand, Brazil, Uzbekistan, and Hungary. This year, BYD also becomes the official partner of UEFA European Football Championship 2024™, showcasing its new energy vehicles on the world stage.

Looking ahead, BYD commits to broadening and deepening localization strategies for its products, technologies, and brand presence across international markets, continuing to drive the global automotive industry towards a greener era.

About BYD

BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.

For more information, please visit www.bydglobal.com.

About BYD Auto

Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, and electronic controllers. It has witnessed in recent years significant technological advancements, including the Blade Battery, DM-i Super Hybrid Technology, e Platform 3.0, CTB Technology, e⁴ Platform, BYD DiSus Intelligent Body Control System, and DMO super hybrid platform. The company is the world's first carmaker to stop the production of fossil-fueled vehicles on the EV shift and has remained top of new energy passenger vehicle sales in China for 11 years in a row.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Asia-Pacific: Liya Huang, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com tel: +56 9 96443906
Brazil: Pablo Toledo, pablo.toledo@byd.com tel: +19 3514 2554
Middle East and Africa: Nikki Li, meapr1@byd.com tel: +86-755-8988-8888-62319

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 09:00:00 EET | Press release

Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s Radio City Music Hall and Intuit Dome in California. “People are seeking richer and more immersive e

Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane ® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.3-6 The lower face plays a pivotal role in overall facial balance, influencing proportions and profile,4 with recent market research conducted by Galderma finding that the chin is the third most treated area in existing HA injectable users.7 In the chin, genetic factors and age-related changes can lead to reduced definition and poor projection.4,8 In the jawline, factors such as

vVARDIS Announces Pricing of Initial Public Offering13.11.2026 07:02:00 EET | Press release

vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file

Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*13.11.2026 00:07:00 EET | Press release

The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release

VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye